TY - JOUR
T1 - Corrigendum to “Design and participant characteristics for a randomized effectiveness trial of an intensive lifestyle intervention to reduce cardiovascular risk in adults with type 2 diabetes
T2 - The I-D-HEALTH study” [Contemp. Clin. Trials 46 (2016) 114–121](S1551714415301191)(10.1016/j.cct.2015.11.008))
AU - Liss, David T.
AU - Finch, Emily A.
AU - Gregory, Dyanna L.
AU - Cooper, Andrew
AU - Ackermann, Ronald T.
N1 - Publisher Copyright:
© 2017
PY - 2018/2
Y1 - 2018/2
N2 - The authors regret that in the above article there were some errors in Table 1 and in corresponding text on baseline characteristics. These errors include the following: 1. Numbers for the Standard Care and GLI groups were inverted for medications variables.2. Selected means and percents were incorrectly rounded for Weight (Standard Care), Total cholesterol (Total, Standard Care), Antilipidemic medications (Total, Standard Care) and Antihypertensive medications (Total, GLI).3. We underreported rates of medication use among the study sample for Antiglycemic medications, Insulin, Other (i.e., non-insulin) antiglycemic medications, Antilipidemic medications and Antihypertensive medications.The Corrected Table 1 should read as presented below, with corrected data in bold. In the Results (page 119), Section 3.2 (Baseline characteristics of the randomized cohort), second paragraph, the description of total cholesterol and HDL cholesterol levels should read: Mean total cholesterol was 171.7 mg/dL (SD 44.9), while mean HDL-C was 44.1 mg/dL (SD 13.1). Mean total cholesterol was 172.0 mg/dL (SD 44.9), while mean HDL-C was 44.1 mg/dL (SD 13.1). In the following paragraph, it should read: More than three-fourths were prescribed antiglycemic medications (87.9%) or antihypertensive medications (76.1%), while more than half were prescribed antilipidemic medications (58.3%). Participants randomized to GLI encouragement were more likely than the Standard Care group to be on antiglycemic medications, both overall (92.7% versus 83.2%, P = 0.008) and for non-insulin antiglycemics (86.0% versus 73.1%, P = 0.004). Original text: More than three-fourths were prescribed antiglycemic medications (87.9%) or antihypertensive medications (76.4%), while more than half were prescribed antilipidemic medications (58.6%). Participants randomized to GLI encouragement were less likely than the Standard Care group to be on antiglycemic medications, both overall (83.2% versus 92.7%, P = 0.008) and for non-insulin antiglycemics (73.1% versus 86.0%, P = 0.004). The authors apologize for any inconvenience caused.
AB - The authors regret that in the above article there were some errors in Table 1 and in corresponding text on baseline characteristics. These errors include the following: 1. Numbers for the Standard Care and GLI groups were inverted for medications variables.2. Selected means and percents were incorrectly rounded for Weight (Standard Care), Total cholesterol (Total, Standard Care), Antilipidemic medications (Total, Standard Care) and Antihypertensive medications (Total, GLI).3. We underreported rates of medication use among the study sample for Antiglycemic medications, Insulin, Other (i.e., non-insulin) antiglycemic medications, Antilipidemic medications and Antihypertensive medications.The Corrected Table 1 should read as presented below, with corrected data in bold. In the Results (page 119), Section 3.2 (Baseline characteristics of the randomized cohort), second paragraph, the description of total cholesterol and HDL cholesterol levels should read: Mean total cholesterol was 171.7 mg/dL (SD 44.9), while mean HDL-C was 44.1 mg/dL (SD 13.1). Mean total cholesterol was 172.0 mg/dL (SD 44.9), while mean HDL-C was 44.1 mg/dL (SD 13.1). In the following paragraph, it should read: More than three-fourths were prescribed antiglycemic medications (87.9%) or antihypertensive medications (76.1%), while more than half were prescribed antilipidemic medications (58.3%). Participants randomized to GLI encouragement were more likely than the Standard Care group to be on antiglycemic medications, both overall (92.7% versus 83.2%, P = 0.008) and for non-insulin antiglycemics (86.0% versus 73.1%, P = 0.004). Original text: More than three-fourths were prescribed antiglycemic medications (87.9%) or antihypertensive medications (76.4%), while more than half were prescribed antilipidemic medications (58.6%). Participants randomized to GLI encouragement were less likely than the Standard Care group to be on antiglycemic medications, both overall (83.2% versus 92.7%, P = 0.008) and for non-insulin antiglycemics (73.1% versus 86.0%, P = 0.004). The authors apologize for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85039560917&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039560917&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2017.08.015
DO - 10.1016/j.cct.2017.08.015
M3 - Comment/debate
C2 - 29292045
AN - SCOPUS:85039560917
SN - 1551-7144
VL - 65
SP - 164
EP - 165
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
ER -